Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580486 | 0.81 | ALOX15 (0.54) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL3584987 | 0.79 | SMN1; SMN2 (0.61) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL13502540 | 0.77 | ALOX15 (0.59) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL8211068 | 0.76 | ALOX15 (0.55) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL8224982 | 0.70 | HPGD (0.74) | KMT2AMEN1NPSR1ALOX15MAPT | |
| SCHEMBL28001619 | 0.69 | ELANE (0.52) | SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL13799881 | 0.68 | ALOX15 (1.00) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL31703144 | 0.68 | ALOX15 (1.00) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL7885140 | 0.67 | ALOX15 (0.54) | KMT2AMEN1NPSR1ALOX15TSHR | |
| SCHEMBL1788116 | 0.66 | ALDH1A1 (0.57) | KMT2AMEN1NPSR1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029658-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | NQO1, SIRT5, KEAP1 | KMT2A 2240/4885MEN1 1210/4885NPSR1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.